<!DOCTYPE html>
<html>
<head>
<title>12_1_MASTER_ALEXION_P03_T05_S02</title>
<meta name="viewport" content="user-scalable=no, width=device-width, initial-scale=1.0, maximum-scale=1.0"/>
<meta name="apple-mobile-web-app-capable" content="yes" />
<meta name="format-detection" content="telephone=no" />


<link href="../global/css/font.css" type="text/css" rel="stylesheet">
<link href="../global/css/global.css" type="text/css" rel="stylesheet">
<link href="css/main.css" type="text/css" rel="stylesheet">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head>
<body>
	<div id="container">
<!--menu top-->
    
    <div class="logo"></div>
    <!--end elements-->
    <div id="main_container" class="bg_orange">
      <div class="claim"> It starts with effective OA<sup>‡</sup> pain relief.</div>
      <div class="title_left brown Helvetica_Round_Bold">
        <i18n id="v2_txt1">VIMOVO provides pain relief
          comparable to celecoxib
          in OA.<sup>1</sup></i18n>
      </div>
      <div class="text_bot HelveticaLTStd_Roman">
        <ul>
          <li>
            <i18n id="v2_txt2">VIMOVO patients with OA of the knee experienced
              improvement in pain relief and function scores,
              comparable to celecoxib at 12 weeks.</i18n>
          </li>
          <li>
            <i18n id="v2_txt3">Patients Global Assessment of osteoarthritis
              response to VIMOVO treatment (PGA-VAS), was
              also comparable to celecoxib at 12 weeks.<sup>1</sup></i18n>
          </li>
        </ul>
      </div>
      <div class="title_chart HelveticaLTStd_Roman">
        <i18n id="v2_txt4"> Mean Change from Baseline in Pain and Function Scores<br>
          at 12 Weeks. Pooled Analysis, Studies 307 and 309</i18n>
      </div>
   
    <div class="chart"></div>
    <div class="shadow"></div>
    <div class="chart_colum"></div>
    <div class="number"></div>
    <div class="name_colum Helvetica_Round_Bold grey">
      <ul>
        <li>
          <i18n id="v2_txt5">WOMAC* Pain</i18n>
        </li>
        <li>
          <i18n id="v2_txt6">WOMAC* Function</i18n>
        </li>
      </ul>
    </div>
    <div class="text_bot_chart grey">
      <ul>
        <li>
          <i18n id="v3_txt7"><span class="blue Helvetica_Round_Bold">VIMOVO</span> (n = 246)<br>
            (500mg EC naproxen, 20mg<br>
            IR esomeprazole BID)</i18n>
        </li>
        <li>
          <i18n id="v3_txt8"><span class="black">Celecoxib</span> (n = 242)<br>
            (200mg OD)</i18n>
        </li>
        <li>
          <i18n id="v3_txt9">Placebo (n = 124)</i18n>
        </li>
      </ul>
    </div>
    <div class="right_colum">
      <ul>
        <li>
          <i18n id="v2_txt10">WOMAC Pain<br>
            p > 0.01 VIMOVO vs placebo<br>
            p > 0.01 celecoxib vs placebo</i18n>
        </li>
        <li>
          <i18n id="v2_txt11">WOMAC Function<br>
            p > 0.01 VIMOVO vs placebo<br>
            p > 0.05 celecoxib vs placebo</i18n>
        </li>
      </ul>
    </div>
    </div>

    <!--End #main_container -->
    <div class="ref_wrapper" id="ref_all"></div>
    <div id="scroll-wrapper" class="scroll_ref">
      <div id="scroller">
        <h1 class="brown Helvetica_Round_Bold">
          <i18n id="v2_v1_S007_ref">References:</i18n>
        </h1>
        <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">1.</span>
          <i18n id="v2_v1_S007_ref_txt0">Hochberg, MC, et al. <span class="HelveticaNeueLTStd_it">Curr Med Res Opin</span> 2011; 27(6): 1243-53.</i18n>
        </div>
        <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">‡</span>
          <i18n id="v2_v1_S007_ref_txt1">Osteoarthritis</i18n>
        </div>
        <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">*</span>
          <i18n id="v2_v1_S007_ref_txt5">Western Ontario and McMaster Osteoarthritis Index</i18n>
        </div>
        <!--end Ref-->
      </div>
      <div class="close"><span class="right"></span></div>
      <div class="arrow_ref"></div>
    </div>

    <!--End area for ref-->

    <div class="info_wrapper" id="info_all"></div>
    <div id="scroll-wrapper" class="scroll_info">
      <div id="scroller">
        <h1 class="brown Helvetica_Round_Bold">
          <i18n id="v2_v1_S007_ref">Study design:</i18n>
        </h1>
        <div class="ref HelveticaLTStd_Roman ref_1">
          <i18n id="info1">Studies 307 and 309 were two randomized, double-blind, parallel-group, placebo-controlled, multi-center phase III studies
    in patients aged ≥ 50 years with symptomatic knee osteoarthritis designed to demonstrate that VIMOVO was non inferior to celecoxib 200mg daily for the treatment of the signs and
    symptoms of OA of the knee; the efficacy of both VIMOVO and celecoxib compared to placebo was also evaluated. Following an osteoarthritis flare, patients received VIMOVO 500/20mg twice daily, celecoxib 200mg once daily, or placebo for 12 weeks. Three co-primary efficacy endpoints were mean change
    from baseline to Week 12 in Western Ontario and McMaster
    Osteoarthritis Index WOMAC Pain, WOMAC Function subscales, and Patient Global Assessment of osteoarthritis using a Visual Analog Scale (PGA-VAS).¹ </i18n>
        </div>
      </div>
      <div class="close"><span class="right"></span></div>
      <div class="arrow_info"></div>
    </div>
</div>

 </body>
	<script type="text/javascript" src="../global/js/config.js"></script>
    <script type='text/javascript' src='../framework/steal/steal.production.js?../framework,development'></script>
	
	<script src="resource:js/SystemBridge.js"></script>
	<script type="text/javascript" src="../global/js/havie.js"></script>
    <script type="text/javascript" src="../global/js/global.js"></script>
    <script type="text/javascript" src="../global/js/ref.js"></script>
    <script type="text/javascript" src="javascript/main.js"></script>	
</html>
   
